MétaCan
Menu
← Back to cohort
Record W4406687771 · doi:10.1093/ecco-jcc/jjae190.1046

P0872 Corticosteroid sparing effects of treatment with guselkumab in patients with moderately to severely active Crohn’s disease: Phase 3 GRAVITI study results through week 48

2025· article· en· W4406687771 on OpenAlexaff
A Hart, Remo Panaccione, Flavio Steinwurz, Qian Cao, Tadakazu Hisamatsu, Stéphane Nancey, Mobolaji Olurinde, Zijiang Yang, Elizabeth Merrall, Natalie A. Terry, Bruce E. Sands

Bibliographic record

VenueJournal of Crohn s and Colitis · 2025
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsUniversity of Calgary
Fundersnot available
KeywordsMedicineCrohn's diseaseCorticosteroidInternal medicineGastroenterologySurgeryDisease

Abstract

fetched live from OpenAlex

Abstract Background The Phase 3 double-blind, placebo-controlled, treat-through GRAVITI study evaluated the efficacy and safety of subcutaneous (SC) induction and maintenance treatment with guselkumab (GUS), a dual-acting IL-23p19 subunit inhibitor that binds to IL-23 and CD64 (a receptor on cells that produce IL-23), in participants (pts) with Crohn’s disease (CD). Here we report the corticosteroid (CS)-sparing effects of treatment with GUS vs placebo (PBO) through Week (Wk) 48. Methods This study randomized pts 1:1:1 to GUS 400mg SC every 4 wks (q4w)→200mg SC q4w, GUS 400mg SC q4w→100mg SC q8w, or PBO. PBO pts who met rescue criteria were eligible for rescue treatment with GUS at Wk16. For pts receiving oral CS at baseline, doses were maintained through Wk12. Mandatory oral CS tapering began at Wk12 unless medically not feasible. CS use, CS-free clinical remission, and 90-day CS-free clinical remission at Wk48 were assessed. Results The full analysis set included 347 pts, mean (SD) age, 37.5 (12.89) yrs; mean CD duration, 8.0 (8.05) yrs; mean (SD) CDAI score, 296.9 (52.68); and mean (SD) SES-CD score, 12.0 (6.94). No pts were receiving beclomethasone at baseline. Among all pts receiving oral CS (prednisone or budesonide) at baseline (103/347; 29.7%), greater proportions of GUS-treated pts (100mg SC q8w: 62.5%, adjusted treatment difference ∆41.7%; 200mg SC q4w: 81.6%, ∆62.9%) were not receiving CS at Wk48 vs PBO (18.2%). Also, among pts receiving oral CS at baseline, greater proportions of GUS-treated pts (100mg SC q8w: 59.4%, ∆38.8%; 200mg SC q4w: 81.6%, ∆62.9%) were not receiving CS for at least 90 days prior to Wk48 vs PBO (18.2%) (Table 1). Significantly greater proportions of GUS-treated pts (100mg SC q8w: 60.0%, ∆42.8%; 200mg SC q4w: 66.1%, ∆48.9%) achieved clinical remission at Wk48 vs PBO (17.1%) (Figure 1). Likewise, greater proportions of GUS-treated pts (100mg SC q8w: 59.1%, ∆42.8%; 200mg SC q4w: 66.1%, ∆49.8%) achieved CS-free clinical remission at Wk48 vs PBO (16.2%). Similarly, greater proportions of GUS-treated pts (100mg SC q8w: 58.3%, ∆41.9%; 200mg SC q4w: 65.2%, ∆49.0%) achieved 90-day CS-free clinical remission at Wk48 vs PBO (16.2%). Conclusion In pts with moderately to severely active CD, greater proportions of GUS-treated pts achieved CS-free efficacy outcomes through Wk48 vs PBO.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.010

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.007
GPT teacher head0.257
Teacher spread0.249 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Crohn s and Colitis→Same topicInflammatory Bowel Disease→French-language works237,207→